Breadcrumb

Asset Publisher

null Group of University Hospital of the Canary Islands (Tenerife)

Hospital Universitario de Canarias (Tenerife)

Description

This is a Clinical-Assistance Group consisting of members of the Infection Section of the University Hospital of the Canary Islands, in La Laguna, Tenerife, and a faculty belonging to the Molecular Diagnosis Section of the Central Laboratory Service of this hospital, under the supervision of Dr Juan Luis Gómez Sirvent.

The group has been associated with Spanish AIDS research Network (RIS) since its inception in 2003 and participates in epidemiologically-based studies and clinical studies in collaboration with other research groups, both in the RIS and beyond. It has also collaborated by collecting and sending clinical data and biological samples in basic research studies related to HIV infection:

Our main lines of interest are:

  • Epidemiological studies about the clinical, demographic and social characteristics, and their evolution over time, of patients with HIV infection in our environment.
  • Studies about the incidence, characteristics and temporal evolution of comorbidities associated with HIV.
  • Study of tolerance and toxicity of antiretroviral drugs in patients with HIV.
  • Studies about the prevalence and clinical consequences of HIV resistance mutations to antiretroviral drugs.
  • Clinical trials on the efficacy and safety of new antiretroviral drugs or new combinations of antiretroviral drugs in HIV patients.
  • Clinical trials on the efficacy and safety of Direct Action Anti-Viral drugs in patients with HIV-HCV coinfection.
  • Studies on the detection, related pathology and their evolution over time of HPV (Human Papillomavirus) infection in HIV patients.

Related Assets

Members

Juan Luis Gómez
Mª Mar Alonso
Felícitas Díaz
Dácil García
Ana López
Ricardo Pelazas

Related Assets

Related Assets

Publications

  • Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial. 
    Santos JR, Llibre JM, Bravo I, García-Rosado D, Cañadas MP, Pérez-Álvarez N, Paredes R, Clotet B, Moltó J.  AIDS Res Hum Retroviruses. 2016 May;32(5):452-5. 
  • Transmitted Drug Resistance to Rilpivirine in Newly Diagnosed Antiretroviral Naïve Adults. 
    Alvarez, Marta; Monge, Susana; Chueca, Natalia; Guillot, Vicente; Anta, Lourdes; Rodriguez, Carmen; Gomez-Sirvent, Juan; Navarro, Gemma; Santos, Ignacio; Moreno, Santiago; Federico, Garcia.  Clinical Microbiology and Infection 2015: 21:104.e1-5. 
  • Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients 
    D. Podzamczer, A. Imaz, I. Perez, P. Viciana, E. Valencia, J. Curto, T. Martý´n, M. Castaño, J. Rojas, N. Espinosa, V. Moreno, V. Asensi, J. A. Iribarren, B. Clotet, L. Force, P. Bachiller, H. Knobel,J. C. Lopez Bernaldo De Quiros, J. R. Blanco, N. Rozas, J. Vergas, A. Ocampo, A. Camacho, J. Flores andJ. L. Gomez-Sirventon behalf of the KIDAR Study Group.  J Antimicrob Chemother 2014;69(9):2536-40. 
  • Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy 
    Juan Berenguer, Bele´n Alejos, Victoria Hernando, Pompeyo Viciana, Miguel Salavert, Ignacio Santos, Juan L. Gómez-Sirvent, Francesc Vidal, Joaquin Portilla, and Julia Del Amo CoRIS (AidsResearch Network Cohort)  AIDS 2012;26 (17): 2241-46 
  • Resistance Platform of the Spanish AIDS Research Network (ResRIS). Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. 
    Poveda E, Anta L, Blanco JL, Casado JL, Gutiérrez F, García F, Gómez-Sirvent JL, Iribarren JA, Soriano V, de Mendoza C;  Antimicrob Agents Chemother. 2010 Jul;54(7):3018-20. 
  • An epidemiologic study to determine the prevalence of theHLA-B*5701 allele among HIV-positive patients in Europe 
    Chloe Orkin, Jianmin Wang, Colm Bergin, Jean-Michel Molina,Adriano Lazzarin, Matthias Cavassini, Stefan Esser,Juan-Luis Gómez Sirvent and Helen Pearce.  Pharmacogenetics and Genomics. 2010:20(5):307-314 
  • HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations. 
    Garriga C, Pérez-Elías MJ, Delgado R, Ruiz L, Pérez-Alvarez L, Pumarola T, López-Lirola A, González-García J, Menéndez-Arias L; Spanish Group for the Study of Antiretroviral Drug Resistance.  J Antimicrob Chemother. 2009 Aug;64(2):251-8. 
  • Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. 
    Gutiérrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Hernández-Quero J, Alemán R, Vidal F, Salavert M, Blanco JR, Leal M, Dronda F, Perez Hoyos S, del Amo J; CoRIS-MD.  Curr HIV Res. 2008 Mar;6(2):100-7 
  • Utility of interrupting antiretroviral treatment before HIV drug resistance testing in patients with persistently detectable low-level viremia. 
    Gómez Sirvent JL, Alonso Socas MM, Hernández Calzadilla C, López Lirola A, Alemán Valls MR.  J Acquir Immune Defic Syndr. 2005; 40 (1): 111-113. 
  • Eficacia del tratamiento antirretroviral en pacientes con infección por el virus de la inmunodeficiencia humana. Estudio de 807 pacientes. 
    MM Alonso Socas, JL Gómez Sirvent, F Santolaria Fernández, F Rodríguez Moreno, H Essardas, E Rodríguez Rodríguez, M Rodríguez Gaspar, C Durán Castellón, R Alemán Valls y E González Reimers.  Medicina Clínica (Barc) 2000; 115: 481- 86. 

Related Assets

Network